The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
CRB-601 and PF-06940434 fall by the wayside.
The company has ditched a trial of drebuxelimab plus ivonescimab.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Persevera is a bust, but Roche hasn’t given up on the front line.
